Jeena Sikho Lifecare
734.70
-5.60(-0.76%)
Market Cap₹9,202.00 Cr
PE Ratio270.11
IndustryHealthcare
Company Performance:
1D-0.76%
1M-12.32%
6M-67.36%
1Y-52.76%
5Y+323.82%
View Company Insightsright
More news about Jeena Sikho Lifecare
12Sept 25
Jeena Sikho Lifecare Limited Expands Operations: New Hospital in Jammu and Digital Partnerships
Jeena Sikho Lifecare Limited (JSLL) has opened a new 40-bed hospital in Jammu, expanding its healthcare services. The facility spans 13,000 sq. ft. and includes 22 rooms and 2 OPDs. Additionally, JSLL has partnered with Salesforce and Quadrafort Technologies to implement digital changes in its Ayurvedic healthcare operations, signaling a commitment to modernization and improved efficiency.
08Sept 25
Jeena Sikho Lifecare Gains Approval for Anti-Diabetes Clinical Trials on Four Products
Jeena Sikho Lifecare has received approval for clinical trials on four anti-diabetes products: SDM02 Tablets, Shuddhi XS Syrup, Petshuddhi Churna, and Shuddhi Dr. B P Care Tablets. Initial trials show promising results in diabetes management without side effects. The company's multi-product approach aims to address various patient needs in diabetes care.
28Aug 25
Jeena Sikho Lifecare Advances Ayurvedic Research with Four Groundbreaking Case Studies
Jeena Sikho Lifecare Limited has published four pioneering case studies in Ayurvedic medicine, co-authored by Managing Director Acharya Manish Grover and associated medical professionals. The studies focus on Ayurvedic approaches to liver health, tubal blockage, early-stage Type 2 diabetes, and liver disease management. The research demonstrates positive outcomes in these areas, highlighting the potential of Ayurvedic treatments as complementary or alternative approaches to conventional medicine. This publication represents the company's commitment to advancing evidence-based Ayurvedic practices and contributes to the growing scientific literature supporting Ayurvedic interventions.
27Aug 25
Jeena Sikho Lifecare Appoints New COO, Approves ESOP Scheme, and Announces Board Changes
Jeena Sikho Lifecare Limited (JSLL) has made significant changes in its leadership and employee benefits structure. Sahil Jain has been appointed as the new Chief Operating Officer. The company has approved an Employee Stock Option Scheme 2025, offering up to 250,000 stock options at Rs. 2.00 per share. Shreya Grover has been redesignated from Non-Executive Director to Whole-Time Director. The Board has also appointed a new Secretarial Auditor, scheduled the 8th AGM, and recommended a final dividend of Rs. 1.10 per equity share.
23Aug 25
Jeena Sikho Lifecare Unveils India's First Triple Detoxification Kit
Jeena Sikho Lifecare Limited has introduced the Pet-Yakrit-Pleeha Shuddhi Kit, India's first triple detoxification product for the gut, liver, and spleen. The launch took place at a press conference in Lucknow, featuring Acharya Manish Ji and Dr. Neha. The product is the result of over 20 years of research and clinical trials, targeting lifestyle-related diseases by addressing root causes. The company has informed both BSE and NSE about the launch through regulatory filings. Additionally, Jeena Sikho Lifecare is considering an Employee Stock Option Scheme, with a Board of Directors meeting scheduled to discuss this potential corporate action.
23Aug 25
Jeena Sikho Lifecare to Consider Employee Stock Option Scheme in Upcoming Board Meeting
Jeena Sikho Lifecare Limited (JSLL) has announced a board meeting on August 27 to consider and approve an Employee Stock Option Scheme (ESOS). The meeting will be held at the company's registered office in Zirakpur, Punjab. JSLL is listed on both NSE (JSLL) and BSE (544476). In a separate development, the company has been empaneled under CBSE to provide medical facilities at various branches, including Vaishali, Gurugram, Delhi, and Meerut.
19Aug 25
Jeena Sikho Lifecare Secures NABH Certification for Agra and Panchkula Hospitals, Releases Q1 FY 2025-26 Earnings Call Recording
Jeena Sikho Lifecare Limited (JSLL) has received NABH certifications for its facilities in Agra and Panchkula, valid until July 21, 2028. The company has made its Q1 FY 2025-26 earnings call recording available online. JSLL's Managing Director, Mr. Manish Grover, is set to attend the Systematix Group – Pharma & Healthcare Conference on August 21, 2025, in Mumbai.
16Aug 25
Jeena Sikho Lifecare Reports Robust 74% Revenue Growth in Q1 FY26
Jeena Sikho Lifecare Limited, an Ayurveda healthcare provider, reported impressive Q1 FY26 results. Revenue increased 74% to ₹174.29 crore, EBITDA grew 220% to ₹78.79 crore, and net profit rose 218% to ₹51.31 crore. The company saw significant growth in patient volumes across IPD, OPD, video consultations, and day care services. Strategic developments include adding 391 new beds, migrating to NSE and BSE mainboard, and launching a new product. Management remains focused on scaling Panchkarma services and driving growth in Medicines & OTC sales for FY26.
14Aug 25
Jeena Sikho Lifecare to Host Q1 FY2025-26 Earnings Conference Call on August 18
Jeena Sikho Lifecare Limited (JSLL) will host a conference call on August 18, 2025, at 4:00 PM IST to discuss Q1 FY2025-26 operational and financial performance. Managing Director Manish Grover and CFO Nanak Chand will lead the call. Dial-in numbers for various countries are provided. JSLL recently reported Q1 revenue of Rs. 17,428.59 lakhs and profit after tax of Rs. 5,131.14 lakhs. The company, which migrated to the Main Board of BSE/NSE on August 11, 2025, operates in Ayurvedic medicines and therapies.
13Aug 25
Jeena Sikho Lifecare Limited Publishes Ayurvedic Research Articles and Announces Investor Events
Jeena Sikho Lifecare Limited has published six research articles on Ayurvedic treatments for various health conditions. The company has scheduled an investor conference call on August 18, 2025, to discuss Q1 FY 2025-26 financial performance. Additionally, Managing Director Manish Grover will attend Antique's Flagship Investor Conference on August 20, 2025, in Mumbai.
26Jun 25
Jeena Sikho Lifecare Secures Approval for 'Shuddhi Dr. Madhumeh' Diabetes Tablet Clinical Trials
Jeena Sikho Lifecare has received approval to conduct clinical trials for its diabetes tablet, 'Shuddhi Dr. Madhumeh'. This marks a significant step in the company's efforts to develop innovative diabetes treatment solutions. The clinical trials will evaluate the safety and efficacy of the tablet, which is designed specifically for diabetic patients. This development could potentially impact the diabetes care landscape, offering new treatment options for millions affected by the condition worldwide.
Jeena Sikho Lifecare
734.70
-5.60
(-0.76%)
1 Year Returns:-52.76%
Industry Peers
Sun Pharmaceutical
1,679.10
(+1.21%)
Divis Laboratories
6,621.50
(+0.32%)
Cipla
1,577.60
(+0.52%)
Torrent Pharmaceuticals
3,584.30
(+1.43%)
Dr Reddys Laboratories
1,255.90
(+1.27%)
Mankind Pharma
2,476.60
(+0.87%)
Zydus Life Science
987.65
(+0.31%)
Lupin
1,940.00
(-0.57%)
Alkem Laboratories
5,581.50
(+1.04%)
Aurobindo Pharma
1,101.00
(-0.48%)